Mediolanum Acquires Phase II-Ready Cancer Vaccine From Italy’s Genovax
This article was originally published in The Pink Sheet Daily
Executive Summary
Italian life sciences seed capital firm Eporgen Venture has used a network of wealthy individuals in Italy to fund a group of new biotech companies, and has entered into its first transaction, selling Genovax’s potential cancer vaccine to Italian pharmaceutical company Mediolanum.